A meta-analysis of 11 studies concludes that self-testing for human papilloma virus (HPV) using urine or vaginal samples accurately detects pre-cancerous cells caused by HPV, also known as high-grade squamous intraepithelial lesions (HSIL+). 

This paper, published in the Journal of Obstetrics and Gynaecology Research, reinforces the precision of self-collection testing for HPV, which could increase access to screening. 

“The outcomes of this investigation indicate that HPV testing performed using both self-collected urine specimen and vaginal specimens achieved a high sensitivity in detecting HSIL+,” wrote the Taiwanese authors. 

High sensitivity for self-collected vaginal swabs

The World Health Organization (WHO) hopes to eliminate cervical cancer by 2030 and sees HPV self-collecting kits as one way to expand screening to reach more women, especially those who have not yet undergone HPV testing. 

The researchers hoped to understand the accuracy of self-testing methods by looking at studies that examined the precision of self-collected HPV kits in finding abnormal cells using urine or vaginal samples. The papers included in the analysis were based on 3,534 self-collected urine samples and 3,523 vaginal samples. 

The distribution of self-sampling kits has the potential to yield a low rate of adverse events and a high level of satisfaction among patients.

Self-collection of urine samples had a pooled sensitivity of 81%, while self-testing with vaginal swabs had a pooled sensitivity of 88.6% for detecting pre-cancerous cells. 

“The meta-analysis corroborated the high sensitivity of HPV testing with self-collected vaginal specimens,” the authors wrote. “The distribution of self-sampling kits has the potential to yield a low rate of adverse events and a high level of satisfaction among patients.” 

Climate change is moving where the malaria hotbeds are in Africa, forcing new regions to contend with the mosquito-borne disease.

Both the malaria parasite and the life cycle of the mosquito vectors, which are cold-blooded, are highly responsive to temperatures, making the disease sensitive to climate change. 

A recent study in Nature finds that rising temperatures have likely increased malaria in high-elevation East and southern Africa, where the weather is typically cooler. At the same time, climate change likely averted a comparable number of cases in West Africa, where temperatures are increasing to a point that it's hot enough to reduce transmission. 

The analysis used 50,425 surveys of malaria infection rates in sub-Saharan Africa, spanning 1900–2016, to calculate monthly averages of the disease at the state or province level. Then, researchers modeled how temperature and extreme precipitation shaped the prevalence of malaria in each region, controlling for factors like seasonality and malaria intervention efforts.

"Over the coming century, we project that climate change could marginally accelerate the elimination of malaria in West and central Africa, where the present-day burden is highest," write the study authors, which include researchers from Yale University, the University of California, Berkeley, and the University of Cape Town.

Malaria mitigation efforts have a larger impact than climate change

Although the effects of climate change on malaria are meaningful, the authors caution that the impact is far smaller than the reductions that have been achieved through medical care, mosquito nets, vector control, and economic development. These investments, they argue, can counterbalance the effects of climate change in most places.

"Malaria elimination within the next generation remains plausible, even in the face of climate change," they said.

They add that future work should explore how emerging methods for predicting climate change could give public health agencies valuable information in preparing for and responding to malaria activity. 

An analysis of invasive Escherichia coli isolates collected from 26 countries found that more than one-third were multidrug-resistant (MDR), researchers reported today in Clinical Infectious Diseases.

The study, by researchers with drugmaker Johnson & Johnson, analyzed more than 10,000 E coli isolates collected from patients with bloodstream infections from 2011 through 2023. The aim of the study was to evaluate the antibiotic resistance, sequence type (ST), and O-serotype distribution of extraintestinal pathogenic E coli (ExPEC), a pathogen that can infect sites outside the intestines and cause invasive E coli disease, or IED, which includes life-threatening conditions like sepsis. 

“Increasing antimicrobial resistance rates and the emergence of multidrug-resistant (MDR) E. coli strains represent a major challenge in the treatment of IED,” the study authors wrote. “In particular, resistance to carbapenems, third-generation cephalosporins, aminoglycosides, or fluoroquinolones is an obstacle to successful treatment.”

34% of E coli  isolates labeled as MDR

Of the 10,098 ExPEC isolates collected, 34% were labeled as MDR, but there was a wide variation between countries. India had the highest MDR rate (83.3%), followed by Mexico (76.6%) and China (69.4%), while the Netherlands (12.1%), New Zealand (11.6%), and Sweden (10.6%) had the lowest MDR rates. Countries with lower income levels tended to have higher rates of MDR E coli.

Overall, serotypes O25, O2, O6, and O1 were the most prevalent. Among the MDR isolates, O25 was the most prevalent in all countries (ranging from 11.3% in China to 56.2% in Mexico). ST131, a globally dominant clone and important cause of urinary tract and bloodstream infections worldwide, accounted for 33% of all MDR isolates.

“Our findings stress the importance of epidemiological studies to monitor the prevalence of high-risk ExPEC clones and highlight the need for ongoing research into novel preventive and therapeutic strategies, including vaccines, to reduce the burden of bacterial disease and limit the spread of antimicrobial resistance,” the authors concluded.